Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Go read this NYT investigation on the inaccuracy of prenatal blood tests

Go read this NYT investigation on the inaccuracy of prenatal blood tests

Blood tests on pregnant people that look for rare and devastating developmental conditions in fetuses are often wrong, according to an investigation from The New York Times.

The blood testing technology, called noninvasive prenatal testing (NIPT), works very well for more common disorders like Down syndrome. But The New York Times reported that a review of data from multiple studies showed that when NIPT is used to test for uncommon things like Wolf-Hirschhorn syndrome (which is found in one in 20,000 births) or Cri-du-chat syndrome (which is found in one in 15,000 births), positive results are wrong 80 percent of the time or more.
O
These tests, made by companies like Natera and Sequenom, have become more popular in recent years. Estimates of the size of the market approach billions of dollars. Positive results on the tests are supposed to trigger more extensive (and accurate) follow-up testing, but those tests are expensive, invasive, and often can’t be done until it would be too late for a legal abortion. Many patients don’t end up getting those follow-up tests, and some terminate pregnancies based on the initial information.

The investigation highlights the statistical challenge of testing for things that are extremely rare. Even a test that’s highly accurate would still find lots of false positives if it was used on thousands of people to try to find a condition that’s only actually there .005 percent of the time (like Wolf-Hirschhorn syndrome). It’s very difficult to create tests for rare conditions that are so good that they won’t have a high number of false positives.

But, as The New York Times reporting found, that issue wasn’t adequately explained to patients who were sold the tests. Companies developing NIPTs used language like “highly accurate” and “total confidence.” Many companies didn’t publish data on their tests’ performance overall, or only stressed data from tests that are more accurate. “I think the information they provide is misleading,” Alberto Gutierrez, the former director of a Food and Drug Administration (FDA) office overseeing medical tests, told The New York Times.

Many NIPTs don’t have to be cleared or reviewed by the FDA before they’re used for patients — they fall under a category called lab-developed tests, which are able to skirt some regulatory oversight. Despite the lack of scrutiny, they’re able to advertise to patients and tout the limited data they have in marketing materials, even if it’s misleading.

Read the full investigation here.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
House Republicans Move to Defund OECD Over Global Tax Dispute
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
Intel Reports Revenue Beats but Sees 81% Rise in Losses
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
CEO Resigns Amid Controversy Over Relationship with HR Executive
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
Tulsi Gabbard Unveils Evidence Alleging Political Manipulation of Intelligence During Trump Administration
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Trump Announces Coca-Cola to Shift to Cane Sugar in U.S. Production
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Air India Pilot’s Mental Health Records Under Scrutiny
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
Moonshot AI Unveils Kimi K2: A New Open-Source AI Model
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Bitcoin Reaches New Milestone of $116,000
Severe Heatwave Claims 2,300 Lives Across Europe
Declining Beer Consumption Signals Cultural Shift in Germany
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
Western Europe Records Hottest June on Record
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
China’s Central Bank Consults European Peers on Low-Rate Strategies
France Requests Airlines to Cut Flights at Paris Airports Amid Planned Air Traffic Controller Strike
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
×